{
    "clinical_study": {
        "@rank": "141513", 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the safety and tolerability of an oral Farnesyl\n      Protein Transferase Inhibitor (SCH 66336) as a single agent in patients with Advanced\n      Myelodysplastic Syndrome, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia in Blast\n      Crisis, or Acute Lymphoblastic Leukemia."
        }, 
        "brief_title": "Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701)", 
        "completion_date": {
            "#text": "March 2004", 
            "@type": "Actual"
        }, 
        "condition": [
            "Leukemia", 
            "Myelodysplastic Syndromes", 
            "Leukemia, Myeloid, Chronic", 
            "Blast Crisis", 
            "Leukemia, Lymphocytic"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Blast Crisis", 
                "Leukemia", 
                "Leukemia, Lymphoid", 
                "Leukemia, Myeloid", 
                "Leukemia, Myelogenous, Chronic, BCR-ABL Positive", 
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Pathologically documented chronic myelogenous leukemia in blast crisis,\n             myelodysplasia, acute myelogenous leukemia, or acute lymphocytic leukemia.\n\n          -  Life expectancy of 12 weeks or greater.\n\n          -  ECOG Performance Status less than or equal to 2.\n\n          -  Meets protocol requirements for specified laboratory values.\n\n          -  No manifestations of a malabsorption syndrome.\n\n        Exclusion Criteria:\n\n          -  Patients who have received more than three chemotherapy regimens for more than three\n             recurrences of the disease.\n\n          -  Poor medical risks because of nonmalignant systemic disease as well as those with\n             active uncontrolled conditions.\n\n          -  Patients who have received investigational therapy of any type within 30 days prior\n             to administration."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "90", 
        "firstreceived_date": "May 1, 2002", 
        "id_info": {
            "nct_id": "NCT00034684", 
            "org_study_id": "P00701"
        }, 
        "intervention": {
            "intervention_name": "Farnesyl Protein Transferase Inhibitor", 
            "intervention_type": "Drug"
        }, 
        "keyword": [
            "Leukemia", 
            "Myelodysplastic Syndromes", 
            "Leukemia, Myeloid", 
            "Leukemia, Lymphocytic"
        ], 
        "lastchanged_date": "October 8, 2013", 
        "official_title": "Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "October 2003", 
            "@type": "Actual"
        }, 
        "removed_countries": {
            "country": [
                "United States", 
                "Canada", 
                "Denmark", 
                "France", 
                "Italy", 
                "Sweden", 
                "United Kingdom"
            ]
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00034684"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2001", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }, 
    "geocoordinates": {}
}